Why did GAAP EPS swing from a loss to a profit year-over-year?

The prior-year quarter included a $3.9 billion acquired IPR&D charge tied to the CymaBay acquisition and a $2.4 billion IPR&D impairment on Immunomedics assets. Those charges did not recur in Q1 2025, so GAAP net income rose to $1.3 billion from a $4.2 billion loss. Higher tax expense and unrealized losses on equity investments partly offset the improvement.

Is the decline in Veklury sales a long-term concern?

Veklury fell 45% to $302 million because COVID-19 hospitalizations declined across regions. Management's full-year guidance assumes only about $1.4 billion in Veklury sales, so this decline is already built into the outlook. The core growth story depends on HIV and Liver Disease rather than Veklury.

What are the key upcoming catalysts for Gilead?

The most important near-term catalyst is the June 19, 2025 PDUFA date for twice-yearly lenacapavir for HIV prevention, which is under FDA priority review. The EMA is also reviewing the application on an accelerated timeline. Positive Phase 3 ASCENT-04 data for Trodelvy plus Keytruda in first-line PD-L1+ triple-negative breast cancer, and a planned Phase 3 study of once-yearly lenacapavir in the second half of 2025, are additional drivers.

Why was GAAP EPS guidance lowered while non-GAAP guidance was unchanged?

GAAP diluted EPS guidance moved to $5.65–6.05 from $5.95–6.35 because the expected impact of acquisition-related and restructuring expenses, equity security fair value adjustments, and discrete tax items rose by about $0.30. Those items are excluded from non-GAAP EPS, which remains at $7.70–8.10, and the company's operating expectations were unchanged.

Is Gilead's dividend and capital return program at risk given the cash decline?

Cash fell to $7.9 billion from $10.0 billion, but that drop reflects a $1.8 billion debt repayment alongside dividends and buybacks. Operating cash flow of $1.8 billion covered the $1.0 billion dividend. The Board declared the $0.79 quarterly dividend, though the filing notes that future dividends remain subject to Board approval.

GILD 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 24, 2025. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences reported first quarter 2025 results on April 24, 2025, with total revenue flat year-over-year at $6.7 billion^a (total revenues $6,667M vs. $6,686M).

The headline story is the quality of the underlying base business: product sales excluding Veklury grew 4% to $6.3 billion^b, led by HIV (+6% to $4.6 billion), with Biktarvy up 7% to $3.1 billion and Descovy up 38% to $586 million. Offsetting weakness came from Veklury (down 45% to $302 million as COVID hospitalizations declined) and Oncology (down 4%, with Trodelvy down 5%). GAAP diluted EPS was $1.04, versus a loss of $(3.34) a year earlier, but that comparison is distorted by the prior-year $3.9 billion CymaBay IPR&D charge and $2.4 billion Immunomedics impairment.

Non-GAAP diluted EPS was $1.81^c, and operating cash flow was $1.8 billion, with free cash flow of $1.65 billion. Capital returns continued during the quarter, with $1.0 billion in dividends, $730 million in share repurchases, and $1.8 billion of senior notes repaid in February. Cash fell to $7.9 billion from $10.0 billion at year-end, reflecting those uses.

Full-year 2025 guidance was largely maintained: product sales of $28.2^d–28.6 billion, and non-GAAP diluted EPS of $7.70–8.10. GAAP diluted EPS guidance was lowered to $5.65–6.05 from $5.95–6.35, driven by higher expected acquisition-related and restructuring charges, fair value adjustments, and tax items rather than a change to the operating outlook.

Key catalysts flagged by management include the June 19, 2025 PDUFA date for twice-yearly lenacapavir for HIV prevention (priority review in the U.S., with EMA review also underway), positive Phase 3 ASCENT-04 data for Trodelvy plus Keytruda in first-line PD-L1+ triple-negative breast cancer, and a planned Phase 3 study of once-yearly lenacapavir in the second half of 2025. The quarterly dividend was declared at $0.79 per share, payable June 27, 2025.

02—Key points

Key Highlights

Total revenue was flat at $6.67 billion, as growth in HIV and Liver Disease offset declines in Veklury (-45%) and Oncology (-4%).
Product sales excluding Veklury rose 4% to $6.31 billion, indicating solid underlying demand for the core portfolio.
Biktarvy sales grew 7% to $3.15 billion, and Descovy grew 38% to $586 million, driven by higher realized price and demand.
GAAP diluted EPS was $1.04 versus $(3.34) a year ago, a swing that mainly reflects non-recurrence of the $3.9B CymaBay IPR&D charge and $2.4B Immunomedics impairment; non-GAAP diluted EPS was $1.81.
Non-GAAP operating margin expanded to 43.4% from (16.7)% a year earlier, and non-GAAP product gross margin was 85.5%.
Free cash flow was $1.65 billion, but cash declined to $7.9 billion after $1.0B in dividends, $730M in buybacks, and $1.8B in debt repayment.
Full-year 2025 non-GAAP diluted EPS guidance was reaffirmed at $7.70–8.10 and product sales at $28.2–28.6B, while GAAP EPS guidance was narrowed lower to $5.65–6.05.

03—Questions

Frequently Asked Questions

Why did GAAP EPS swing from a loss to a profit year-over-year?
The prior-year quarter included a $3.9 billion acquired IPR&D charge tied to the CymaBay acquisition and a $2.4 billion IPR&D impairment on Immunomedics assets. Those charges did not recur in Q1 2025, so GAAP net income rose to $1.3 billion from a $4.2 billion loss. Higher tax expense and unrealized losses on equity investments partly offset the improvement.
Is the decline in Veklury sales a long-term concern?
Veklury fell 45% to $302 million because COVID-19 hospitalizations declined across regions. Management's full-year guidance assumes only about $1.4 billion in Veklury sales, so this decline is already built into the outlook. The core growth story depends on HIV and Liver Disease rather than Veklury.
What are the key upcoming catalysts for Gilead?
The most important near-term catalyst is the June 19, 2025 PDUFA date for twice-yearly lenacapavir for HIV prevention, which is under FDA priority review. The EMA is also reviewing the application on an accelerated timeline. Positive Phase 3 ASCENT-04 data for Trodelvy plus Keytruda in first-line PD-L1+ triple-negative breast cancer, and a planned Phase 3 study of once-yearly lenacapavir in the second half of 2025, are additional drivers.
Why was GAAP EPS guidance lowered while non-GAAP guidance was unchanged?
GAAP diluted EPS guidance moved to $5.65–6.05 from $5.95–6.35 because the expected impact of acquisition-related and restructuring expenses, equity security fair value adjustments, and discrete tax items rose by about $0.30. Those items are excluded from non-GAAP EPS, which remains at $7.70–8.10, and the company's operating expectations were unchanged.
Is Gilead's dividend and capital return program at risk given the cash decline?
Cash fell to $7.9 billion from $10.0 billion, but that drop reflects a $1.8 billion debt repayment alongside dividends and buybacks. Operating cash flow of $1.8 billion covered the $1.0 billion dividend. The Board declared the $0.79 quarterly dividend, though the filing notes that future dividends remain subject to Board approval.

04—Continue

← View all 8-K filings